{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:03:59Z","timestamp":1773216239109,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejca.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T22:19:40Z","timestamp":1664835580000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial"],"prefix":"10.1016","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-1836","authenticated-orcid":false,"given":"Andrea B.","family":"Apolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-6629","authenticated-orcid":false,"given":"Burcin","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Scheffold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2022.09.020_bib1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2022.09.020_bib2","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2022.09.020_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2022.09.020_bib4","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.09.020_bib5","series-title":"US highlights of prescribing information","year":"2022"},{"key":"10.1016\/j.ejca.2022.09.020_bib6","series-title":"Opdivo - Summary of product characteristics","year":"2022"},{"issue":"5","key":"10.1016\/j.ejca.2022.09.020_bib7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/PPO.0000000000000477","article-title":"Novel therapeutic approaches and the evolution of drug development in advanced kidney cancer","volume":"26","author":"Ravi","year":"2020","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.ejca.2022.09.020_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/jnci\/djaa064","article-title":"Summary from the first Kidney Cancer Research Summit, September 12-13, 2019: a focus on translational research","volume":"113","author":"Choueiri","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.020_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","article-title":"Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma","volume":"18","author":"Braun","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2022.09.020_bib10","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.ejca.2022.09.020_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.2020.38.4_suppl.478","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040","volume":"38","author":"Yau","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ejca.2022.09.020_bib12","doi-asserted-by":"crossref","first-page":"TPS4592","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4592","article-title":"Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH)","volume":"39","author":"McGregor","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.ejca.2022.09.020_bib13","doi-asserted-by":"crossref","first-page":"TPS767","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS767","article-title":"A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk","volume":"38","author":"Choueiri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.09.020_bib14","series-title":"Exelixis announces cabozantinib in combination with nivolumab and ipilimumab significantly improved progression-free survival in phase 3 COSMIC-313 pivotal trial in patients with previously untreated advanced kidney cancer","year":"2022"},{"issue":"suppl 7","key":"10.1016\/j.ejca.2022.09.020_bib15","first-page":"S808","article-title":"Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). LBA8","volume":"33","author":"Choueiri","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.09.020_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"282","key":"10.1016\/j.ejca.2022.09.020_bib17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"suppl 6","key":"10.1016\/j.ejca.2022.09.020_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/JCO.2021.39.6_suppl.3","article-title":"Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors","volume":"39","author":"Apolo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.09.020_bib19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.09.020_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102333","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"suppl 5","key":"10.1016\/j.ejca.2022.09.020_bib21","first-page":"664P","article-title":"Final results from phase I trial of cabozantinib\/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors","volume":"32","author":"Kydd","year":"2021","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922007602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:04Z","timestamp":1760733484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922007602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"alternative-id":["S0959804922007602"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}